Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Invested Capital (2020 - 2026)

Bioventus filings provide 6 years of Invested Capital readings, the most recent being $478.1 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 1.14% to $478.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $478.1 million, a 1.14% decrease, with the full-year FY2025 number at $478.1 million, down 1.14% from a year prior.
  • Invested Capital hit $478.1 million in Q4 2025 for Bioventus, down from $497.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $965.3 million in Q4 2021 to a low of $232.6 million in Q3 2021.
  • Median Invested Capital over the past 5 years was $546.5 million (2024), compared with a mean of $527.1 million.
  • Biggest five-year swings in Invested Capital: soared 506.52% in 2021 and later tumbled 54.13% in 2023.
  • Bioventus' Invested Capital stood at $965.3 million in 2021, then dropped by 14.14% to $828.8 million in 2022, then dropped by 27.49% to $601.0 million in 2023, then decreased by 19.53% to $483.6 million in 2024, then dropped by 1.14% to $478.1 million in 2025.
  • The last three reported values for Invested Capital were $478.1 million (Q4 2025), $497.1 million (Q3 2025), and $537.5 million (Q2 2025) per Business Quant data.